Diabetes T-Shirt Contest

Further to my rally cry on maintaining a positive attitude, hop on over to my pal Gina’s site DiabetesTalkFest to enter the T-shirt contest (no photos necessary, and no water involved
Some of my favorite slogans submitted so far include “Hit me with your best shot!,” “Diabetics do it with a prick,” “Bleed Daily,” and “My sister got diabetes…. and all I got was this stupid T-shirt.” Hurry! All entries must be in by April…

Read more »

Bad News, You Can’t Use

I am in total agreement with Violet over at Pumplandia that the influx of negative diabetes news gets you DOWN. That’s why I’m trying to make this blog an upbeat place. I did say “encouragement” in the header for a reason
You know what? I kind of had my blinders on before I started this blog: I figured all I needed to know was how to use the equipment they gave me, and screw everything…

Read more »

Diabetes? Do Tell …

I want to thank the many people who responded to last week’s posting** on talking publicly about being diabetic (lots of emails). It is heartening to know that most of you are quite open about your diabetes, at least in your personal lives. (Although I need to keep my eyes peeled in public restrooms –- our No.1 refuge, it seems.)
A number of people were skeptical about “talking” at work, and suggested a “need-to-know” policy…

Read more »

Amylin’s Other Profit Injection

What I hear is that the pharma industry (and Wall Street) is holding its breath for Amylin’s next big thing: Exenatide (produced in partnership with Eli Lilly & Co.). This is another injectable product (derived from lizard saliva, of all things!) that, if approved by the FDA in a few months, will be offered in a pen delivery system. This one’s mainly for Type 2 diabetics, and clinical studies have shown “marked reductions in blood…

Read more »

Amylin’s Symlin Not so Hot?

The FDA approval of Symlin is making big headlines, and last week I had a bunch of relatives contact me, as they tend to do, when something new and “hot” appears on the diabetes scene. The drug is targeted toward Type 1 diabetics who don’t achieve good BG control despite insulin treatments. It was apparently 18 years in the making, and is the first new drug to be marketed to Type 1 diabetics since insulin…

Read more »